Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Fucoidan - Alaria
2. Fucoidan - Ecklonia
3. Fucoidan - Durvillea
4. Fucoidan - Sargassum
5. Fucoidan - Cladosiphon
6. Fucoidan - Fucus Serratus
7. Fucoidan - Fucus Vesiculosus
8. Fucoidan - Laminaria Digitata
9. Fucoidan - Ascophyllum Nodosum
10. Fucoidan - Laminaria Japonicia
11. Fucoidan - Lessonia Nigrescens
12. Fucoidan - Macrocystis Pyrifera
13. Fucoidan - Pelvetia Canaliculata
14. Zinc97974745
15. Yf01606
16. Yf09360
17. Yf09361
18. Yf09362
19. Yf09363
20. Yf57714
21. Yf145109
22. Yf146833
23. Yf146834
24. Yf153483
25. Yf157138
26. Yf157165
27. Yf157166
28. Yf157167
29. Fucoidan - Ascophyllum Nodosum, Analytical Grade
30. (2s,3s,4s,5s,6r)-4,5-dihydroxy-2,6-dimethyltetrahydro-2h-pyran-3-yl Hydrogen Sulfate
| Molecular Weight | 242.25 g/mol |
|---|---|
| Molecular Formula | C7H14O7S |
| XLogP3 | -1.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Exact Mass | 242.04602395 g/mol |
| Monoisotopic Mass | 242.04602395 g/mol |
| Topological Polar Surface Area | 122 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 308 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Fucoidan is a dietary supplement drug, which is currently being evaluated in clinical studies for the treatment of aging.
Lead Product(s): Fucoidan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Sponsor: University of Rochester | L'Oreal | DoNotAge.org
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 30, 2026
Lead Product(s) : Fucoidan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : University of Rochester | L'Oreal | DoNotAge.org
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fucoidan is a dietary supplement drug, which is currently being evaluated in clinical studies for the treatment of aging.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
March 30, 2026
Details:
Whey Protein is a protein drug, which is currently being evaluated in clinical studies for the treatment of aging.
Lead Product(s): Whey Protein,Creatine Monohydrate,Fucoidan,Urolithin A,Nicotinamide Mononucleotide,Multivitamin,L-Ergothioneine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Sponsor: Xprize Foundation | Abinopharm Inc | DoNotAge.org
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 05, 2026
Lead Product(s) : Whey Protein,Creatine Monohydrate,Fucoidan,Urolithin A,Nicotinamide Mononucleotide,Multivitamin,L-Ergothioneine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Xprize Foundation | Abinopharm Inc | DoNotAge.org
Deal Size : Inapplicable
Deal Type : Inapplicable
PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)
Details : Whey Protein is a protein drug, which is currently being evaluated in clinical studies for the treatment of aging.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 05, 2026
Details:
The acquisition of VISUfarma, with its broad portfolio of innovative eye health products, including Xailin Ectoine, aligns with Lupin's strategy to expand its European business.
Lead Product(s): Hyaluronic Acid,Ectoine,Fucoidan
Therapeutic Area: Ophthalmology Brand Name: Xailin Ectoine
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2025
Lead Product(s) : Hyaluronic Acid,Ectoine,Fucoidan
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lupin Strengthens its Ophthalmology Business with Acquisition of VISUfarma
Details : The acquisition of VISUfarma, with its broad portfolio of innovative eye health products, including Xailin Ectoine, aligns with Lupin's strategy to expand its European business.
Product Name : Xailin Ectoine
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 29, 2025
Details:
Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Lead Product(s): Fucoidan,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Sponsor: Nutrasource | University of South Carolina
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2022
Lead Product(s) : Fucoidan,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Nutrasource | University of South Carolina
Deal Size : Inapplicable
Deal Type : Inapplicable
Inflammatory and Immune Response After High Intensity Exercise
Details : Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
March 14, 2022
Details:
Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Lead Product(s): Fucoidan,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Dietary Supplement
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 22, 2020
Details : Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
October 22, 2020
Details:
Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Lead Product(s): Fucoidan,Icosapent Ethyl,DHA
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Sponsor: Three Peace Co., Ltd., Japan
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 21, 2011
Lead Product(s) : Fucoidan,Icosapent Ethyl,DHA
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Three Peace Co., Ltd., Japan
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of a Supplement Containing Fucoidan on Basal Body Temperature
Details : Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 21, 2011
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info : Cancelled
Registration Country : Spain
Rhamnus Purshiana Dc. Powder; Cynara Scolymus L. Dry Extract; Peumus Boldus M. Dry Extract; Aloe Ferox Mill.
Brand Name : Nico-Hepatocyn Coated Tablets
Dosage Form : Film Coated Tablet
Dosage Strength :
Packaging :
Approval Date : 01-07-1945
Application Number : 6726
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Cancelled
Registration Country : Spain
Rhamnus Purshiana Dc. Powder; Cynara Scolymus L. Dry Extract; Fucus Vesiculosus Exto Dry
Brand Name : Zimema Coated Tablets
Dosage Form : Film Coated Tablet
Dosage Strength :
Packaging :
Approval Date : 01-11-1950
Application Number : 14302
Regulatory Info : Cancelled
Registration Country : Spain
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
13
PharmaCompass offers a list of Fucoidan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fucoidan manufacturer or Fucoidan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fucoidan manufacturer or Fucoidan supplier.
A Fucoidan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fucoidan, including repackagers and relabelers. The FDA regulates Fucoidan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fucoidan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fucoidan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Fucoidan supplier is an individual or a company that provides Fucoidan active pharmaceutical ingredient (API) or Fucoidan finished formulations upon request. The Fucoidan suppliers may include Fucoidan API manufacturers, exporters, distributors and traders.
click here to find a list of Fucoidan suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
Fucoidan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fucoidan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fucoidan GMP manufacturer or Fucoidan GMP API supplier for your needs.
A Fucoidan CoA (Certificate of Analysis) is a formal document that attests to Fucoidan's compliance with Fucoidan specifications and serves as a tool for batch-level quality control.
Fucoidan CoA mostly includes findings from lab analyses of a specific batch. For each Fucoidan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fucoidan may be tested according to a variety of international standards, such as European Pharmacopoeia (Fucoidan EP), Fucoidan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fucoidan USP).
